Biomarkers as predictors of recurrence following curative resection for pancreatic ductal adenocarcinoma: A review

Sylvester N. Osayi, Mark Bloomston, Carl M. Schmidt, E. Christopher Ellison, Peter Muscarella

Research output: Contribution to journalReview article

9 Scopus citations

Abstract

Pancreatic ductal adenocarcinoma (PDA) is the fourth most common cancer causing death in the United States. Early tumor recurrence is an important contributor to the dismal prognosis. The availability of an accurate prognostic biomarker for predicting disease recurrence following curative resection will be beneficial for patient care. Most of the currently studied biomarkers remain in the investigational phase, with CA 19-9 being the only biomarker currently approved by the FDA. Herein, we review the utility of CA 19-9 and other investigational cellular, gene, and molecular tumor markers for predicting PDA recurrence following curative surgical resection.

Original languageEnglish (US)
Article number468959
JournalBioMed Research International
Volume2014
DOIs
StatePublished - 2014

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Fingerprint Dive into the research topics of 'Biomarkers as predictors of recurrence following curative resection for pancreatic ductal adenocarcinoma: A review'. Together they form a unique fingerprint.

  • Cite this